[Transplant coronary artery disease--treatment with statins]

Pol Merkur Lekarski. 2004 May;16(95):472-3.
[Article in Polish]

Abstract

Hypercholesterolemia is a common disorder after heart transplantation and my be associated with the development of transplant coronary artery disease. 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors (HMG CoA) are the most effective drugs to lower cholesterol level in transplant patients. However, interaction of immunosuppressants with HMG CoA inhibitors, which are metabolized by cytochrome P 450, increase incidence of skeletal muscle myopathy and rhabdomyolysis.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / etiology
  • Cyclosporine / adverse effects*
  • Cytochrome P-450 Enzyme System / metabolism
  • Drug Interactions
  • Heart Transplantation / adverse effects*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / etiology
  • Rhabdomyolysis / chemically induced*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cyclosporine
  • Cytochrome P-450 Enzyme System